Chloroquine

Administration

  • Type: Antimalarial
  • Dosage Forms:
  • Routes of Administration: Oral
  • Common Trade Names: (Aralen)

Adult Dosing

Most malaria-endemic areas have high rates of chloroquine resistance. Per the CDC, chloroquine-sensitive areas include: Central America west of the Panama Canal, Haiti, the Dominican Republic, and most of the Middle East. See [CDC malaria information by country] for details

  • Uncomplicated malaria treatment: 1000 mg PO, followed by 500mg PO at 6, 24, and 48 hours after first dose
  • Malaria prophylaxis: 500 mg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure

Pediatric Dosing

  • Uncomplicated malaria treatment: 16.6 mg/kg PO (max 1 g), followed by 8.3 mg/kg PO at 6, 24, and 48 hours after first dose
  • Malaria prophylaxis: 8.3 mg/kg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure

Special Populations

  • Pregnancy Rating: C
  • Lactation risk: Infant risk minimal
  • Renal dosing: reduce dose by 50% if CrCl < 10
  • Hepatic dosing: may need serum drug level monitoring as 30-50% of dose modified by liver

Contraindications

  • Allergy to class/drug
  • Retinal or visual field changes

Adverse Reactions

Serious

  • Prolonged QT, AV block
  • Heart failure
  • SJS
  • Neutropenia
  • Extrapyramidal disease
  • Seizure
  • Retinopathy

Common

Pharmacology

  • Half-life: 1-2 months
  • Metabolism: Hepatic
  • Excretion: Renal, fecal

Mechanism of Action

  • Precise mechanism unknown, action thought to be due to interaction with DNA

Comments

See Also

References

Authors:

Claire